Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback